Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types

Presentations include initial results for an investigational combination of fianlimab (LAG-3 inhibitor) and Libtayo (PD-1 inhibitor) in advanced n...

Related Keywords

Israel ,Geneva ,Genè ,Switzerland ,Canada ,Brazil ,Georged Yancopoulos ,Regeneron Velocimmune ,Regeneron Pharmaceuticals ,Regeneron Pharmaceuticals Inc ,Regeneron Genetics Center ,Drug Administration ,Clinical Sciences ,Regeneron Velocimmune Technology ,Nasdaq ,Exchange Commission ,Oncology Esmo Io Congress ,European Society For Medical Oncology Immuno ,European Union ,European Society ,Medical Oncology Immuno ,Israel Lowy ,Senior Vice President ,Nonproprietary Naming ,Biological Products Guidance ,Indications Libtayo ,Prescribing Information ,Chief Scientific Officer George ,Regeneron Genetics ,Looking Statements ,Product Candidates ,